Moving lentiviral-based gene therapy into a first-in-man CF trial

Moving lentiviral-based gene therapy into a first-in-man CF trial

Bibliographische Detailangaben
Hauptverfasser:	Griesenbach, D, Alton, E, Beekman, J, Boyd, A, Chan, M, Davies, J, Davies, L, Davidson, H, Dekkers, F, Gea-Sorli, S, Gill, D, Hasegawa, M, Higgins, T, Hyndman, L, McLachlan, G, Inoue, M, Hyde, S, Moran, C, Meng, C, Paul-Smith, M, Pringle, I, Pytel, K, Rodriguez-Martinez, A, Stevenson, B, Tsugumine, S
Format:	Conference item
Sprache:	English
Veröffentlicht:	Wiley 2015

Ähnliche Einträge

Preparation for a first-in-man lentivirus trial in cystic fibrosis patients
von: Griesenbach, U, et al.
Veröffentlicht: (2016)

Production of SIV-F/HN: a new Lentivirus vector for CF gene therapy
von: Hyde, S, et al.
Veröffentlicht: (2015)

TOXICOLOGY STUDIES IN SUPPORT OF THE UK CF GENE THERAPY CONSORTIUM'S MULTI-DOSE CLINICAL TRIAL
von: Griesenbach, U, et al.
Veröffentlicht: (2011)

Genetic medicines for CF: Hype versus reality
von: Alton, E, et al.
Veröffentlicht: (2016)

Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis.
von: Alton, E, et al.
Veröffentlicht: (2016)

EVALUATION OF SAFETY AND GENE EXPRESSION WITH A SINGLE DOSE OF PGM169/GL67A ADMINISTERED TO THE NOSE AND LUNG OF INDIVIDUALS WITH CF: THE UK CF GENE THERAPY CONSORTIUM "PILOT STUDY"
von: Davies, J, et al.
Veröffentlicht: (2009)

SAFETY AND EXPRESSION OF A SINGLE DOSE OF LIPID-MEDIATED CFTR GENE THERAPY TO THE UPPER AND LOWER AIRWAYS OF PATIENTS WITH CF
von: Davies, J, et al.
Veröffentlicht: (2011)

Update on the UK CF Gene Therapy Consortium Multidoes, non-viral, gene therapy trial
von: Alton, E, et al.
Veröffentlicht: (2012)

UPDATE ON THE UK CF GENE THERAPY CONSORTIUM MULTIDOSE, NON-VIRAL, GENE THERAPY TRIAL
von: Alton, E, et al.
Veröffentlicht: (2012)

UPDATE ON THE UK CF GENE THERAPY CONSORTIUM MULTIDOSE, NON-VIRAL, GENE THERAPY TRIAL
von: Alton, E, et al.
Veröffentlicht: (2012)

EVALUATION OF SAFETY AND GENE EXPRESSION WITH A SINGLE DOSE OF PGM169/GL67A ADMINISTERED TO THE NOSE AND LUNG OF INDIVIDUALS WITH CYSTIC FIBROSIS: THE UK CF GENE THERAPY CONSORTIUM "PILOT STUDY''
von: Davies, J, et al.
Veröffentlicht: (2009)

A PHASE 2B DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF NON-VIRAL MEDIATED GENE THERAPY FOR CF
von: Alton, E, et al.
Veröffentlicht: (2013)

Towards a first-in-human trial with a pseudotyped lentivirus
von: Alton, EW, et al.
Veröffentlicht: (2020)

OPTIMISATION OF MOLECULAR ASSAYS FOR CLINICAL TRIAL OF GL67A/PDNA DELIVERY TO NOSE AND LUNG OF CF PATIENTS
von: Sumner-Jones, S, et al.
Veröffentlicht: (2009)

Recombinant Sendai virus vector to evaluate vector distribution in a large animal model of lung gene transfer
von: McLachlan, G, et al.
Veröffentlicht: (2004)

DEVELOPMENT, PRODUCTION AND EVALUATION OF CLINICAL GRADE CFTR EXPRESSION PLASMID FOR CF LUNG GENE THERAPY
von: Gill, DR, et al.
Veröffentlicht: (2010)

Gene therapy for respiratory diseases; progress and a changing context
von: Alton, EWFW, et al.
Veröffentlicht: (2020)

597: Protocol development for mouse toxicology studies using lentiviral gene therapy
von: Sinadinos, A, et al.
Veröffentlicht: (2021)

REPEAT ADMINISTRATION OF GL67A/PGM169 IS FEASIBLE, SAFE, AND PRODUCES ENDOGENOUS LEVELS OF CFTR EXPRESSION AFTER 12 DOSES
von: Alton, E, et al.
Veröffentlicht: (2012)

Toxicology study assessing efficacy and safety of repeated administration of lipid/DNA complexes to mouse lung.
von: Alton, E, et al.
Veröffentlicht: (2014)

Cumulative CFTR expression following repeated aerosol delivery of non-viral pGM169/GL67A formulation to mouse lung
von: Alton, E, et al.
Veröffentlicht: (2012)

Toxicology study assessing efficacy and safety of repeated administration of lipid/DNA complexes to mouse lung
von: Alton, E, et al.
Veröffentlicht: (2014)

Development of lentiviral vector respiratory tract dosing methods in anticipation of rodent GLP toxicology assessment
von: Sinadinos, A, et al.
Veröffentlicht: (2021)

The lung as a factory to produce secreted intrapulmonary and circulatory proteins
von: Paul-Smith, M, et al.
Veröffentlicht: (2017)

EXERCISE CAPACITY AND PHYSICAL ACTIVITY IN PATIENTS WITH CF: DATA FROM THE UK CF GENE THERAPY CONSORTIUM (UKCFGTC) 'RUN-IN' STUDY
von: Saunders, C, et al.
Veröffentlicht: (2010)

UKCF gene therapy consortium tracking study: Sputum and serum calprotectin are useful novel measurements in CF exacerbation
von: Gray, R, et al.
Veröffentlicht: (2007)

The murine lung as a factory to produce secreted intrapulmonary and circulatory proteins
von: Paul-Smith, M, et al.
Veröffentlicht: (2018)

3-STEP TAQMAN RT-PCR: ULTIMATE MESSENGER RNA DETECTION SENSITIVITY FOR CF GENE THERAPY CLINICAL TRIALS
von: McCormick, D, et al.
Veröffentlicht: (2009)

Pre-existing immunity to human parainfluenza virus (hPIV) does not affect rSIV.F/HN-mediated transduction efficiency
von: Pytel, K, et al.
Veröffentlicht: (2016)

SAFETY AND EXPRESSION OF A SINGLE DOSE OF LIPID-MEDIATED CFTR GENE THERAPY TO THE UPPER AND LOWER AIRWAYS OF PATIENTS WITH CYSTIC FIBROSIS
von: Davies, G, et al.
Veröffentlicht: (2011)

Assessment of selected media supplements to improve F/HN lentiviral vector production yields
von: Gélinas, J, et al.
Veröffentlicht: (2017)

Pre-clinical evaluation of three non-viral gene transfer agents for cystic fibrosis after aerosol delivery to the ovine lung.
von: McLachlan, G, et al.
Veröffentlicht: (2011)

Cholesterol as an enhancer of lentiviral vector production in serum-free transient transfection
von: Gelinas, J, et al.
Veröffentlicht: (2013)

LONGITUDINAL ASSESSMENT OF BIOMARKERS FOR CLINICAL TRIALS OF NOVEL THERAPEUTIC AGENTS: THE RUN-IN STUDY
von: Alton, E, et al.
Veröffentlicht: (2010)

A method for assessing the distribution of eGFP expressing cells in the mouse lung following lentiviral vector transduction
von: Munday, R, et al.
Veröffentlicht: (2018)

A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis
von: Alton, E, et al.
Veröffentlicht: (2013)

A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis.
von: Alton, E, et al.
Veröffentlicht: (2013)

Large-scale, high-throughput production of lentiviral vectors for multiple disease applications
von: Ashworth, R, et al.
Veröffentlicht: (2018)

Recombinant Sendai virus vector to evaluate vector distribution in a large animal model of lung gene transfer
von: McLachlan, G, et al.
Veröffentlicht: (2004)

LONGITUDINAL ASSESSMENT OF BIOMARKERS FOR CLINICAL TRIALS OF NOVEL THERAPEUTIC AGENTS; THE RUN-IN STUDY
von: Alton, E, et al.
Veröffentlicht: (2010)